← Back to Search


CapTem Plus Radioembolization for Neuroendocrine Tumor Liver Metastases(CapTemY90 Trial)

Phase 2
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with at least one measurable liver metastases, with size > 1cm (RECIST criteria)
Women of child bearing potential and fertile men are required to use effective contraception (negative serum βHCG for women of child-bearing age)
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up2 years
Awards & highlights
No Placebo-Only Group

CapTemY90 Trial Summary

This trial is testing a combination of drugs to treat neuroendocrine tumors that have spread to the liver. The drugs are capecitabine, temozolomide, and yttrium-90 radioembolization. The study is to see if this combination is more effective than other treatments and has fewer side effects.

Eligible Conditions
  • Neuroendocrine Tumors
  • Liver Metastases

CapTemY90 Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below
You have a blockage in the main vein that carries blood to your liver.
You are expected to live for at least 6 more months.

CapTemY90 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
intra-hepatic progression-free survival
Secondary outcome measures
Chromogrannin A level
Intra-hepatic and extra-hepatic tumor responses
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

CapTemY90 Trial Design

1Treatment groups
Experimental Treatment
Group I: CapTemY90Experimental Treatment1 Intervention
Capecitabine 600 mg/m2 twice daily for 14 days and temozolomide 150-200 mg/m2 in two divided doses on Days 10-14, with 14 days between cycles, to be continued until 1) disease progression or 2) intolerable toxicities. During the initial cycle of CapTem, simulation angiography for Y-90 radioembolization planning will be performed. Once the patient has successfully completed the first cycle of CapTem and undergone simulation demonstrating eligibility for Y-90 radioembolization, the dominant lobe will be treated on Day 7 of the 2nd cycle of CapTem. Resin microspheres will be prescribed according to the BSA method per the manufacturer's Instructions for Use. If the other hepatic lobe needs to be treated, this will be done on Day 7 of the 3rd or 4th cycle of CapTem.

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
105,102 Total Patients Enrolled
2 Trials studying Neuroendocrine Tumors
212 Patients Enrolled for Neuroendocrine Tumors
Roswell Park Cancer InstituteOTHER
390 Previous Clinical Trials
30,099 Total Patients Enrolled
3 Trials studying Neuroendocrine Tumors
96 Patients Enrolled for Neuroendocrine Tumors
2 Previous Clinical Trials
550 Total Patients Enrolled
1 Trials studying Neuroendocrine Tumors
50 Patients Enrolled for Neuroendocrine Tumors

Media Library

Capecitabine (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT04789109 — Phase 2
Neuroendocrine Tumors Research Study Groups: CapTemY90
Capecitabine (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04789109 — Phase 2
Neuroendocrine Tumors Clinical Trial 2023: Capecitabine Highlights & Side Effects. Trial Name: NCT04789109 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are the combination of Capecitabine tablets, temozolomide tablets, and SIR-Spheres supported by a federal stamp of approval?

"On the basis of Phase 2 data, our team at Power rated capecitabine tablets + temozolomide tablets + SIR-Spheres a score of two for safety; albeit there is evidence to support its security, no studies have confirmed its efficacy."

Answered by AI

Are there any reports detailing the effects of taking Capecitabine tablets in combination with temozolomide tablets and SIR-Spheres?

"Currently, 531 studies involving the combination of Capecitabine tablets + temozolomide tablets + SIR-Spheres are actively recruiting participants. Of these trials, 149 have reached Phase 3 and a total of 16,516 locations across the world are running them. Adelaide in South Australia is among the sites hosting these investigations."

Answered by AI

Is this experimental protocol new to the field?

"Since 2002, comprehensive research has been conducted into the effects of Capecitabine tablets + temozolomide tablets + SIR-Spheres. The initial trial was funded by Schering-Plough and involved 60 participants—prompting Phase 2 drug approval in due course. Nowadays, 531 active studies are taking place across 70 nations and 2291 cities."

Answered by AI

Are researchers currently looking for volunteers to join this experiment?

"Affirmative. Clinicaltrials.gov reveals that this research endeavour, first posted on November 1st 2021, is seeking volunteers at present. The clinical trial requires 55 individuals to register from a single medical centre."

Answered by AI

How many individuals are enrolled in this investigation?

"Affirmative. clinicaltrials.gov has the latest information on this medical investigation, which was originally posted in November 2021 and last modified in October of that same year. The exploration is seeking 55 individuals to participate at a single trial centre."

Answered by AI

What disease or condition would necessitate treatment with Capecitabine tablets, temozolomide tablets and SIR-Spheres?

"For managing progression of the illness, Capecitabine tablets + temozolomide tablets + SIR-Spheres is often recommended. Additionally, this combination can be advantageous for patients dealing with nitrosourea treatment, advance directives and refractory advanced mycosis fungoides."

Answered by AI
~18 spots leftby Dec 2024